These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 9366427

  • 1. Costimulation provided by DNA immunization enhances antitumor immunity.
    Corr M, Tighe H, Lee D, Dudler J, Trieu M, Brinson DC, Carson DA.
    J Immunol; 1997 Nov 15; 159(10):4999-5004. PubMed ID: 9366427
    [Abstract] [Full Text] [Related]

  • 2. CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo.
    Agadjanyan MG, Kim JJ, Trivedi N, Wilson DM, Monzavi-Karbassi B, Morrison LD, Nottingham LK, Dentchev T, Tsai A, Dang K, Chalian AA, Maldonado MA, Williams WV, Weiner DB.
    J Immunol; 1999 Mar 15; 162(6):3417-27. PubMed ID: 10092797
    [Abstract] [Full Text] [Related]

  • 3. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.
    Baskar S, Clements VK, Glimcher LH, Nabavi N, Ostrand-Rosenberg S.
    J Immunol; 1996 May 15; 156(10):3821-7. PubMed ID: 8621919
    [Abstract] [Full Text] [Related]

  • 4. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors.
    Schirmbeck R, Böhm W, Reimann J.
    J Immunol; 1996 Oct 15; 157(8):3550-8. PubMed ID: 8871655
    [Abstract] [Full Text] [Related]

  • 5. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
    De Veerman M, Heirman C, Van Meirvenne S, Devos S, Corthals J, Moser M, Thielemans K.
    J Immunol; 1999 Jan 01; 162(1):144-51. PubMed ID: 9886380
    [Abstract] [Full Text] [Related]

  • 6. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS, Chung SW, Kim SH, Kang BY, Hwang SY, Lee JW.
    Cancer Gene Ther; 2000 Jun 01; 7(6):861-9. PubMed ID: 10880016
    [Abstract] [Full Text] [Related]

  • 7. The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo.
    Sigal LJ, Reiser H, Rock KL.
    J Immunol; 1998 Sep 15; 161(6):2740-5. PubMed ID: 9743331
    [Abstract] [Full Text] [Related]

  • 8. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N, Brown JM, Demcheva M, Kelley JR, Lockett MA, Vournakis J, Cole DJ.
    Clin Cancer Res; 1999 May 15; 5(5):1173-82. PubMed ID: 10353754
    [Abstract] [Full Text] [Related]

  • 9. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
    Guinn BA, DeBenedette MA, Watts TH, Berinstein NL.
    J Immunol; 1999 Apr 15; 162(8):5003-10. PubMed ID: 10202049
    [Abstract] [Full Text] [Related]

  • 10. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
    Wild J, Grusby MJ, Schirmbeck R, Reimann J.
    J Immunol; 1999 Aug 15; 163(4):1880-7. PubMed ID: 10438922
    [Abstract] [Full Text] [Related]

  • 11. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
    Kim TS, Lee BC, Kim E, Cho D, Cohen EP.
    Vaccine; 2008 Nov 05; 26(47):5928-34. PubMed ID: 18793691
    [Abstract] [Full Text] [Related]

  • 12. The roles of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA.
    Chan K, Lee DJ, Schubert A, Tang CM, Crain B, Schoenberger SP, Corr M.
    J Immunol; 2001 Mar 01; 166(5):3061-6. PubMed ID: 11207256
    [Abstract] [Full Text] [Related]

  • 13. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.
    Moro M, Gasparri AM, Pagano S, Bellone M, Tornaghi P, Veglia F, Corti A, Casorati G, Dellabona P.
    Cancer Res; 1999 Jun 01; 59(11):2650-6. PubMed ID: 10363988
    [Abstract] [Full Text] [Related]

  • 14. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
    Bian Y, Hiraoka S, Tomura M, Zhou XY, Yashiro-Ohtani Y, Mori Y, Shimizu J, Ono S, Dunussi-Joannopoulos K, Wolf S, Fujiwara H.
    Int Immunol; 2005 Jan 01; 17(1):73-83. PubMed ID: 15569772
    [Abstract] [Full Text] [Related]

  • 15. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes.
    Ishioka GY, Fikes J, Hermanson G, Livingston B, Crimi C, Qin M, del Guercio MF, Oseroff C, Dahlberg C, Alexander J, Chesnut RW, Sette A.
    J Immunol; 1999 Apr 01; 162(7):3915-25. PubMed ID: 10201910
    [Abstract] [Full Text] [Related]

  • 16. Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide.
    Chung SW, Cohen EP, Kim TS.
    Vaccine; 2004 Jun 30; 22(20):2547-57. PubMed ID: 15193380
    [Abstract] [Full Text] [Related]

  • 17. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination.
    Thomson SA, Sherritt MA, Medveczky J, Elliott SL, Moss DJ, Fernando GJ, Brown LE, Suhrbier A.
    J Immunol; 1998 Feb 15; 160(4):1717-23. PubMed ID: 9469429
    [Abstract] [Full Text] [Related]

  • 18. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
    Maecker HT, Umetsu DT, DeKruyff RH, Levy S.
    J Immunol; 1998 Dec 15; 161(12):6532-6. PubMed ID: 9862678
    [Abstract] [Full Text] [Related]

  • 19. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines.
    Iwasaki A, Stiernholm BJ, Chan AK, Berinstein NL, Barber BH.
    J Immunol; 1997 May 15; 158(10):4591-601. PubMed ID: 9144471
    [Abstract] [Full Text] [Related]

  • 20. Intramuscular gene transfer of soluble B7.1/IgG(1) fusion cDNA induces potent antitumor immunity as an adjuvant for DNA vaccination.
    Zhou ZF, Peretz Y, Chang Y, Miao DS, Li X, Prud'homme GJ.
    Cancer Gene Ther; 2003 Jun 15; 10(6):491-9. PubMed ID: 12768195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.